Regeneron (REGN) Reports Dupixent Recommended for EU Approval by the CHMP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Regeneron (REGN) Reports Dupixent Recommended for EU Approval by the CHMP

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

September 20, 2024 7:45 AM EDT

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in adults and adolescents

If approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age group

TARRYTOWN, N.Y. and PARIS, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending... More